Shionogi boosts Tetra Alzheimer's deal, nabs buyout option

In a high-stakes game for both companies, Shionogi is doubling down on its Tetra Therapeutics R&D deal with a buyout option wedded to key data coming out this month.

The pair’s original pact was penned back in late 2018 and saw Tetra team up with Shionogi to advance its PDE4-targeting drug in Alzheimer’s disease (AD) and fragile X syndrome.